5414x -

Co-founder and CEO announced he will step down from his role and the board by the end of 2026.

The full regulatory document can be accessed through the London Stock Exchange or financial news platforms like ADVFN . Interim results for the 6 months ended 30 June 25

: Established a strategic collaboration with Cepheid (a Danaher subsidiary) to develop automated infectious disease sequencing solutions. Leadership Update Co-founder and CEO announced he will step down

: Continued advancement in national programs like NIHR Bioresource. Strategic and Operational Developments

: £12.9 million (+27.4%), supported by synthetic biology. : Introduced next-generation automated flow cell lines and

"5414X" is the RNS (Regulatory News Service) identifier for the released by Oxford Nanopore Technologies plc .

: Introduced next-generation automated flow cell lines and strengthened quality assurance to ISO 13485 standards. Co-founder and CEO announced he will step down

: A refined commercial strategy identified high-priority opportunities in applied and research markets worth an estimated $13 to $14 billion .